Tariquidar-ondansetron Combination in Neuropathic Pain
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
Prospective, randomized, double-blind, placebo controlled, cross-over proof of concept study.
To determine the pharmacokinetics and tolerability of co-administration of 5-HT3R antagonist
ondansetron with a P-glycoprotein inhibitor tariquidar, in patients with neuropathic pain.